PL3200828T3 - Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych - Google Patents
Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnychInfo
- Publication number
- PL3200828T3 PL3200828T3 PL15848100T PL15848100T PL3200828T3 PL 3200828 T3 PL3200828 T3 PL 3200828T3 PL 15848100 T PL15848100 T PL 15848100T PL 15848100 T PL15848100 T PL 15848100T PL 3200828 T3 PL3200828 T3 PL 3200828T3
- Authority
- PL
- Poland
- Prior art keywords
- neurological
- disorders
- treatment
- neurodegenerative diseases
- intranasal compositions
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903944A AU2014903944A0 (en) | 2014-10-03 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders | |
| PCT/AU2015/050591 WO2016049700A1 (en) | 2014-10-03 | 2015-09-30 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
| EP15848100.2A EP3200828B1 (en) | 2014-10-03 | 2015-09-30 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3200828T3 true PL3200828T3 (pl) | 2021-01-25 |
Family
ID=55629161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15848100T PL3200828T3 (pl) | 2014-10-03 | 2015-09-30 | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10471040B2 (enExample) |
| EP (1) | EP3200828B1 (enExample) |
| JP (3) | JP2017530195A (enExample) |
| AU (1) | AU2015327762C1 (enExample) |
| CA (1) | CA2961936C (enExample) |
| DK (1) | DK3200828T3 (enExample) |
| ES (1) | ES2822562T3 (enExample) |
| HU (1) | HUE052441T2 (enExample) |
| PL (1) | PL3200828T3 (enExample) |
| PT (1) | PT3200828T (enExample) |
| SM (1) | SMT202000576T1 (enExample) |
| WO (1) | WO2016049700A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000576T1 (it) * | 2014-10-03 | 2020-11-10 | Lachesis Biosciences Ltd | Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi |
| AR111699A1 (es) * | 2017-02-02 | 2019-08-14 | Otolanum Ag | Composición farmacéutica que comprende betahistina |
| WO2021258150A1 (en) * | 2020-06-25 | 2021-12-30 | Lachesis Biosciences Limited | Methods of treating or preventing organophosphorus poisoning |
| EP4221645A4 (en) * | 2020-10-01 | 2024-10-02 | Lyra Therapeutics, Inc. | Osmotic drug delivery implants |
| CN115919767B (zh) * | 2022-10-13 | 2023-08-11 | 暨南大学 | 卡巴拉汀鼻喷雾剂及其制备方法 |
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5733M (enExample) | 1966-09-27 | 1968-01-22 | ||
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| FR2722989B1 (fr) | 1994-07-29 | 1997-05-30 | Synthelabo | Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales |
| US6558560B2 (en) * | 2001-07-27 | 2003-05-06 | Hewlett-Packard Company | Method for the fabrication of electrical contacts |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| DE602005010899D1 (de) * | 2004-09-27 | 2008-12-18 | Sigmoid Pharma Ltd | Mikrokapseln mit einem methylxanthin und einem kortikosteroid |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| EP1933809B1 (en) * | 2005-10-11 | 2012-02-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| KR20080097443A (ko) * | 2006-02-03 | 2008-11-05 | 아바니르 파마슈티컬스 | 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물 |
| EP1981475A2 (en) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Pharmaceutical formulations |
| EP2172224A4 (en) * | 2007-06-26 | 2013-01-16 | Wakamoto Pharma Co Ltd | AQUEOUS COMPOSITION |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| US8673338B2 (en) * | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| SMT202000576T1 (it) * | 2014-10-03 | 2020-11-10 | Lachesis Biosciences Ltd | Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi |
-
2015
- 2015-09-30 SM SM20200576T patent/SMT202000576T1/it unknown
- 2015-09-30 JP JP2017536991A patent/JP2017530195A/ja active Pending
- 2015-09-30 PT PT158481002T patent/PT3200828T/pt unknown
- 2015-09-30 HU HUE15848100A patent/HUE052441T2/hu unknown
- 2015-09-30 DK DK15848100.2T patent/DK3200828T3/da active
- 2015-09-30 PL PL15848100T patent/PL3200828T3/pl unknown
- 2015-09-30 AU AU2015327762A patent/AU2015327762C1/en active Active
- 2015-09-30 US US15/516,233 patent/US10471040B2/en active Active
- 2015-09-30 CA CA2961936A patent/CA2961936C/en active Active
- 2015-09-30 EP EP15848100.2A patent/EP3200828B1/en active Active
- 2015-09-30 WO PCT/AU2015/050591 patent/WO2016049700A1/en not_active Ceased
- 2015-09-30 ES ES15848100T patent/ES2822562T3/es active Active
-
2019
- 2019-09-13 US US16/569,986 patent/US10933045B2/en active Active
-
2020
- 2020-03-04 JP JP2020036966A patent/JP7357571B2/ja active Active
-
2021
- 2021-01-27 US US17/160,009 patent/US11911360B2/en active Active
- 2021-10-20 JP JP2021171712A patent/JP2022003100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015327762C1 (en) | 2020-10-22 |
| US20170239209A1 (en) | 2017-08-24 |
| US20200078331A1 (en) | 2020-03-12 |
| US11911360B2 (en) | 2024-02-27 |
| JP2017530195A (ja) | 2017-10-12 |
| US10471040B2 (en) | 2019-11-12 |
| SMT202000576T1 (it) | 2020-11-10 |
| CA2961936A1 (en) | 2016-04-07 |
| JP2022003100A (ja) | 2022-01-11 |
| AU2015327762A1 (en) | 2017-04-20 |
| JP2020090547A (ja) | 2020-06-11 |
| PT3200828T (pt) | 2020-10-08 |
| JP7357571B2 (ja) | 2023-10-06 |
| HUE052441T2 (hu) | 2021-04-28 |
| WO2016049700A1 (en) | 2016-04-07 |
| EP3200828B1 (en) | 2020-08-12 |
| DK3200828T3 (da) | 2020-10-12 |
| US20210145789A1 (en) | 2021-05-20 |
| ES2822562T3 (es) | 2021-05-04 |
| EP3200828A4 (en) | 2018-04-25 |
| CA2961936C (en) | 2023-03-14 |
| AU2015327762B2 (en) | 2020-06-25 |
| US10933045B2 (en) | 2021-03-02 |
| EP3200828A1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| IL248732B (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| PL3200828T3 (pl) | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| LT3458067T (lt) | Neurologinių sutrikimų gydymas | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| GB201411616D0 (en) | Diagnosis and treatment of neurodegenerative disorders | |
| HK40066377A (zh) | 治疗神经疾病的组合物和方法 | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
| AU2014903944A0 (en) | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders | |
| IL254140A0 (en) | Preparations and combinations for use in the treatment of angiogenic diseases and disorders |